Anika Therapeutics Stock
Anika Therapeutics Stock
Our community is currently high on Anika Therapeutics with 5 Buy predictions and 0 Sell predictions.
With a target price of 28 € there is a slightly positive potential of 18.64% for Anika Therapeutics compared to the current price of 23.6 €.
Pros and Cons of Anika Therapeutics in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Anika Therapeutics vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Anika Therapeutics | - | 4.425% | -4.065% | -4.839% | 15.686% | -39.175% | -30.812% |
Evolus Inc | 2.610% | 2.609% | 0.000% | 44.785% | 30.387% | 26.203% | - |
Ardelyx Inc. | 3.070% | 1.608% | 0.032% | 93.211% | 9.308% | 11.823% | - |
Salarius Pharmaceuticals Inc. | - | -3.015% | -16.087% | -67.833% | -30.450% | -98.515% | -99.994% |
Comments
Anika Therapeutics, Inc. (NASDAQ: ANIK) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $37.00 price target on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
Anika Therapeutics, Inc. (NASDAQ: ANIK) had its price target raised by analysts at Barrington Research from $28.00 to $29.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
Anika Therapeutics, Inc. (NASDAQ: ANIK) had its price target raised by analysts at Barrington Research from $24.00 to $28.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANIK provided by MarketBeat